Drug intelligence / Profile preview

QR-435

Development stage: Preclinical
Lead developer: Quigley Pharma
Modality: Small Molecules
Administration: Inhalation, Topical

Overview

QR-435 is an all-natural antiviral formulation developed by Quigley Pharma, primarily composed of green tea extract and horseradish (at a concentration of at least 50%). It was specifically designed to protect against viral infections, with a primary focus on the influenza A virus H3N2 strain. Preclinical research, including studies in ferret models and in vitro assays, demonstrated its efficacy in preventing viral transmission and providing prophylaxis. Additionally, the compound has been utilized in impregnated masks to effectively block the passage of live viruses.

Beyond the preview

Go deeper on QR-435.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QR-435.

Explore the full profile